



DAFTAR PUSTAKA

- Abramowitz, M. & Stegun, I. A., 1970, *Handbook of Mathematical Functions with Formulas, Graphs, and Mathematical Tables*, McGraw-Hill, USA.
- Andreeff, M. (ed.), 2015, *Targeted Therapy of Acute Myeloid Leukemia: Current Cancer Research*, Springer-Verlag, New York.
- Akagi, T., Ogawa, S., Dugas, M., dkk, 2009, Frequent Genomic Abnormalities in Acute Myeloid Leukemia/Myelodysplastic Syndrome with Normal Karyotype, *Haematologica* vol. 94: 213 – 223. doi:10.3324/haematol.13024.
- Arkun, Y., 2016, Dynamic Modeling and Analysis of the Cross-Talk Between Insulin-AKT and MAPK/ERK Signaling Pathways, *PLoS ONE*, vol. 11, no. 3: e0149684. doi:10.1371/journal.pone.0149684.
- Bakta, I. M., 2006, *Hematologi Klinis Ringkas*, Penerbit Buku Kedokteran EGC :Jakarta Hlm:120 – 148.
- Bartholdy, B., Christopeit, M., Will, B., Mo, Y., dkk, 2014, HSC Commitment-associated epigenetic signature is prognostic in acute Myeloid Leukemia, *The Journal of Clinical Investigation*, vol. 124, no. 3, March 2014.
- Beagle, B. & Fruman, D. A., 2015, The PI3K-AKT-mTOR Signaling Network in AML, dalam *Targeted Therapy of Acute Myeloid Leukemia*, Andreeff, M. Ed. USA: Springer, 335 – 362.
- Behar, M., Barken, D., Wener, S. L., Hoffmann, A., 2013, The Dynamics of Signaling as a Pharmacological Target, *Cell*, vol. 155, no. 2.
- Besse, A., Clapp, G. D., Bernard, S., dkk, 2018, Stability Analysis of a Model of Interaction Between the Immune System and Cancer Cell in Chronic Myelogenous Leukemia, *Bull. Math. Biol.*, vol. 80, no. 5: 1084 – 1110.

- Bozzone, D., 2009, *The biology of Cancer : Leukemia*, Chelsea House Pub. New York.
- Brandts, C. H., Sargin, B., Rode, M., dkk, 2005, Constitutive Activation of Akt by Flt3 Internal Tandem Duplications is Necessary for Increased Survival, Proliferation, and Myeloid Transformation, *Cancer Res*, vol. 65, no. 21: 9643 – 9650.
- Buonomo, B., 2015, A Note on the Direction of the Transcritical Bifurcation in Epidemic Models, *Nonlinear Analysis:Modelling and Control*, vol. 20, no. 1: 38 - 55.
- Carneiro, B. A., Kaplan, J. B. , Altman, J. K., dkk, 2015. Targeting mTOR Signalling Pathways and Related Negative Feedback Loops for The Treatment of Acute Myeloid Leukemia, *Cancer Biology and Therapy* 16:5; 648 – 656, DOI 10.1080/15384047.2015.1026510
- Chavez C. C. & Song, B., 2004, Dynamical Model of Tuberculosis and Their Applications, *Math. Biosci. Eng.*, vol.1, no. 2: 361 – 404.
- Chen, J., Odenika, O., Rowley, J. D., 2010, Leukemogenesis : More Than Mutant Genes, *Nat. Rev. Cancer*, vol.10, no. 1: 23 – 36, doi:10.1038/nrc2765.
- Chitnis, N., Hyman, J. M., and Cushing, J. M., 2008, Determining important parameters in the spread of malaria through the sensitivity analysis of a mathematical model, *Bull. Math. Biol.*, vol. 70, no. 5: 1272 – 1296.
- Clapp, G. D. & Levy, D., 2015, A Review of Mathematical Models for Lymphoma and Leukemia, *Drug Discovery Today: Disease Models*, Vol. 16: 1 – 6.
- Cucuianu, A. and Precup, R., 2010, A Hypothetical Mathematical Model of Acute Myeloid Leukemia Pathogenesis, *Computational and Mathematical Methods in Medicine* vol.11, no. 1: 49 – 65

- Dohner, H., Weisdorf D. J., Bloomfield, C. D., 2015, Acute Myeloid Leukemia, *New England Journal of Medicine* 373 (12): 1136 - 1152. doi: 10.1056/NEJM-ra1406184.
- Dohner, H., Estey, E., Grimwade, D., 2017, Diagnosis and Management of AML in AdultsL 2017 ELN Recommendations From an International Expert Panel, *Blood*, vol. 129, no. 4: 424 - 447.
- Faduola, P., Hakim, A., Mansnerus, J., dkk, 2013, Acute Myeloid leukemia: Therapy past, present, dan future, *Translation Biomedicine*, vol. 4 No.2:1, doi:10.3823/440
- Foley, C. and Makey, M. C., 2009, Dynamic Hematological Diseases : A Review, *J Mathematical Biology* Vol. 58(1-2): 285–322
- Forsythe, A., Brandt, P. S., Dolph, M., dkk , 2018, Systematic Review of Helath State Utility Values for Acute Myeloid Leukemia, *ClinicoEconomics and Outcomes Research*, vol. 2018, no. 10, 83 –92.
- Fransecky, L., Mochmann, L. H., and Baldus, C. D., 2015, Outlook on PI3K/AKT/mTOR inhibition in Acute Leukemia. *Molecular and Cellular Therapies* vol.3, no. 2.
- Gantmacher, F., 1959, *Applications of the Theory of Matrices*, New York: Interscience.
- Garcia, M. L. & Bear, M. R., 2017, FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions, *Mol Cancer Ther.* 2017, vol. 16, no. 6: 991 – 1001.
- Garcia, J. S., Percival, M. E., 2017, Midostourin for the Treatment of Adult Patients with Newly Diagnosed Acute Myleoid Leukemia that is FLT3 Mutation Positif, *Drug of Today.* 2017, vol. 53, no. 10: 531 – 543.

- Grafone T., Palmisano M., Nici C., Storti S., 2012, An Overview on The Role of FLT3 Tyrosine Kinase Receptor in Acute Myeloid Leukemia: Biology and Treatment, *Oncology Reviews*, vol. 6:e8.
- Grimwade D., Ivey A., and Huntly B. J. P, 2016, Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance, *Blood*, vol. 127, no. 1, DOI 10.1182/blood-2015-07-604496.
- Hatakeyama, M., Kimura, S., Naka, T., dkk, 2003, A Computational Model on The Modulation of Mitogen Activated Protein Kinase (MAPK) and AKT Pathways in Hergulin Induced ErbB Signalling, *Biochem J*, vol. 373: 451 – 463.
- Hatzimichael, E., Georgiou, G., Benetatos, L., and Briasoulis, E., 2013, Gene Mutations and Molecularly Targeted Therapies in Acute Myeloid Leukemia, *Am J. Blood Res*, vol. 3: 29 – 51.
- Herschbein, L. & Liesveld, L., 2018, Dueling for dual inhibition: Means to enhance effectiveness of PI3K/AKT/mTOR inhibitors in AML, *Boold Review*, vol. 32, no. 3:235 - 248.
- Horne, G. A., Kinstrie, R., Copland, M., 2015, Novel drug therapies in myeloid leukemia, *Pharm. Pt. Anal.*, vol. 4, no. 3: 187 – 205.
- Horton, S. J & Huntly, B. J. P., 2012, Recent advances in acute myeloid leukemia stem cell biology, *Haematologica*, vol. 97: 966-974; doi:10.3324/haematol.2011.054734
- Ingalls ,B. P., 2013, *Mathematical Modelling in System Biology: An Introduction*, MIT Press, Cambridge.
- Jane-Bain, B., 2014, *Hematologi: Kurikulum Inti*, EGC, Jakarta.
- Kadia, T. M., Ravandi, F., Cortes, J., and Kantarjian, H., 2016, New drugs in acute myeloid leukemia, *Annals of Oncology* , vol. 27: 770 – 778, doi:10.1093/annonc/mdw015.

- Karabekmez, R., 2013, *Modeling of Cancer Signaling*, UWSpace, Canada.
- Kayser, S. & Levis, M., 2018, Advanced in Targeted Therapy for Acute Myeloid Leukemia. *Br J. Haematol*, vol. 180, no. 4:484 – 500.
- Keener, J. & Sneyd, J., 1998, *Mathematical Physiology 8*, Springer-Verlag, New York.
- Khalil, H. K., 2002, *Nonlinear Systems*, Prentice-Hall Inc., USA.
- Klipp, E., Liebermeister, W., Wierling, C., dkk, 2009. *Systems Biology: A Textbook*. Weinheim: Wiley-VCH
- Koh, G., Teong, H. F. C., Clement, M. V., Hsu, D., and Thiagarajan, P. S., 2006, A decomposition approach to parameter estimation in pathway modeling : a case study of the Akt and MAPK pathways and their crosstalk. *Bioinformatic*, vol. 22, no. 14: e271 - e280.
- Kornblau, S. M., Singh, N., Qiu, Y. H., dkk, 2010, High Phosphorylated FOXO3a is an Adverse Prognostic Factor in Acute Myeloid Leukemia, *Clin Cancer Res.*, vol. 16, no. 6: 1865 – 1875.
- Kosasih, A. S., Setiawan, L., Hartini, S., dkk, 2011, Immunophenotyping in the Diagnosis and Classification of Acute Leukimia: Dharmais Cancer Hospital Experience, *Ind. Journal of Cancer*, vol. 5, no. 1: 3 – 8.
- Kouchkovsky, I. D, Abdul-Hay M., 2016, Acute Myeloid Leukemia: A Comprehensive Review and 2016 Update, *Blood Cancer Journal*, vol. 2016, no. 6, e441; doi:10.1038/bcj.2016.50.
- Kuznetsov, Y. A, 1998, *Element of Applied Bifurcation Theory*. Springer Verlag New York, Inc.
- Layek, G.C., 2015, *An Introduction to Dynamical Systems and Chaos*, Springer, New Dehli.

- Leskovac, V., 2003, *Comprehensive Enzyme Kinetics*, Kluwer Academic Publishers, New York.
- Levis, M., 2017, Midostourin Approved for FLT3-mutated AML. *Blood*, vol. 129, no. 26:3403 – 3406.
- Lindblad, O., Cordero, E., Puissant, A., dkk, 2016, Aberant Activation of The Pi-k/mTOR Pathway Promotes Resistance to Sorafenib in AML, *Oncogene*, 1 - 13.
- Lynch, S. 2014, *Dynamical System with Applications Using MATLAB*, Birkhauser, London
- MacLean, A. L., Lo, C. C., Stumpf, M. P. H., 2013, Population dynamics of normal and leukaemia stem cells in the haematopoietic stem cell niche show distinct regimes where leukaemia will be controlled. *J. R. Soc. Interface*, vol.10: 20120968, <http://dx.doi.org/10.1098/rsif.2012.0968>
- Mackey, M. C., Ou, C., Pujo-Menjouet, L., Wu, J., 2006, Periodic Oscilation of Blood Cell Population in Cronic Myelogenous Leukemia, *SIAM J. Math Anal.*, vol. 38, no. 1: 166 – 187.
- Martelli, M. P., Sportoletti, P., Tiacci, E., Martelli, M. F., and Falini, B., 2013, Mutation Lanscape of AML with normal Cytogenetics: Biological and Clinical Implications, *Blood Review*, vol. 27: 13 – 22.
- Martinez-Climent, J. A., Fontan, L., dkk., Lymphoma stem cells: enough evidence to support their existence?, *Haematologica*, 2010, 95:293-302. doi:10.3324/haematol.2009.013318.
- Nanda, S., Depillis, L., Radunskaya, 2013, B Cell Cronic Lymphocytic Leukemia- A Model with Immune Response, *Discrete and Continuous Dynamical Systems Series B*, vol. 18, no. 4: 1053 – 1076.
- National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 1. 2016 Acute Myeloid Leukemia. National Comprehensive Cancer Network.

- National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients Acute Myeloid Leukemia (Version 1.2018) Feb 5; National Comprehensive Cancer Network.
- Nguyen, H. P., Hang, D. T., Ly, Q. T., dkk, 2015, Targeting PI3K/AKT/mTOR signaling in Acute Myeloid Leukemia. *Vietnam Journal of Science*, vol. 2, no. 2: 11 – 16.
- Nho, R. S. & Hergert, P., 2014, FoxO3a and Disease Progression. *World J. Biol. Chem.*, vol. 5, no. 3: 346 – 354.
- Nordigarden, A., 2013, *The FLT3 Tyrosine Kinase in Leukemia: Deciphering The Downstream Signaling Events and Drug-Escape Mechanisms*. Disertasi, Linkoping University, Swedia. Dapat diakses melalui <http://www.diva-portal.org/smash/get/diva2:602086/FULLTEXT01.pdf>
- Nurmalasari, S. S., Widjajanto, P. H., Mulatsih, S., Purwanto, I., 2012, Leukemia Myeloblastik Akut: Luaran Terapi di RSUP DR. Sardjito, Yogyakarta, 2004 – 2008, *Indonesian Jour. of Cancer*, vol. 6: 49 – 52.
- Nurnberg, B. & Beer-Hammer, S., 2019, Function, Regulation and Biological Roles of PI3K γ Variants, *Biomolecules*, vol. 9, no. 427.
- Ozbay, H., Bonnet, C., Benjelloum, H., Clairambault, J., 2012, Stability Analysis of Cell Dynamics in Leukemia. *Mat. Model. Nat. Phenom.*, vol. 7, no. 1: 203 – 234.
- Pandolfi, A., Barreyro, L., Steidl, U., 2013, Concise Review: Preleukemic Stem Cell: Molecular Biology and Clinical Implications of the Precursors to leukemia Stem Cells. *Stem Cell Translational Medicine*, vol. 2: 143 – 150. <http://dx.doi.org/10.5966/sctm.2012-0109>.
- Park, S., Chapuis, N., Tamburini, J., dkk., Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia, *Haematologica*, vol. 95, no. 5: 819- 828. doi:10.3324/haematol.2009.013797.

- Perko, L., 2006, *Differential Equations and Dynamical Systems. Text in Applied Mathematics 7*. Springer-Verlag, New York.
- Polak, R. & Buitenhuis, 2012, The PI3K/PKB signaling Module as key Regulator of Hematopoiesis : Implications for Therapeutic Strategies in Leukemia. *Blood*, vol. 119, no. 4.
- Pu, T., Zhang, X., Liu, F., Wang, W., 2010, Coordination of the Nuclear and Cytoplasmic Activities of p53 in Response to DNA Damage, *Biophysical Journal*, vol. 99: 1696 – 1705.
- Price, N., Stevens, L., 1989, *Fundamentals of Enzymology*, Oxford University Press, USA.
- Reikvam, H., Tamborini, J., Skrede, S., dkk, 2014, Antileukemic Effect of PI3K-mTOR inhibitors in Acute Myeloid Leukemia-gene Expression Profiles Reveal CDC25B Expression as Determine of Pharmacological effect. *Brit. J. of Haematology*, vol. 164: 200 – 211.
- Rubinov, S. I. & Lebowitz, J. L., 1976, A Mathematical Model of The Acute Myeloblastic Leukemic State in Man, *Biophysical Journal*, vol. 16: 897 – 910.
- Santamaria, C. M., Chillon, M. C., Gracia-Sanz, R., dkk, 2009, High FOXO3a Expression is Associated with a Poorer Prognosis in AML with Normal Cytogenetics, *Leukemia Research* 33: 1706 - 1709.
- Sauro, H. M., 2011, *Enzyme Kinetics for Systems Biology* (Ambrosius Pub, Washington, 2011).
- Schiller, G. J., Tuttle, P., Desai, P., 2016, Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post Transplantation, *Biol. Blood Marrows Transplant*, vol. 22: 982 – 990.

- Sharma, M. & Mohanty, S., 2013, Molecular Biomarkers in Cytogenetically Normal Acute Myeloid Leukemia: Hanessing the Targets, *J. Mol Biomarkers Diagnosis*, S8:009.Doi:10.4172/2155-9929.S8-009.
- Shen Y., Bai J., He A., 2016, Review Article; Role of mTOR signaling pathway in acute myeloid leukemia, *Int. J. Clin. Exp. Med*, vol. 9, no. 2: 637 – 647.
- Simanjorang, C., Kodim, N., Tehuteru, E., 2013, Perbedaan Kesintasan 5 tahun Pasien Leukemia Limpoblastik Akut dan Leukimia Mieloblastik Akut pada Anak di Rumah Sakit kanker Dharmais, Jakarta, 1997 – 2008. *Ind. Journal of Cancer*, vol. 7, no. 1: 15 – 21.
- Stiehl, T., Baran, N., Ho, A. D., Marchianiak-Czohcra, A., 2014, Selection and Therapy Resistance in Acute Myeloid Leukemia: MATHematical Modelling Explains Different Proliferation Pattern at Diagand Relapse. *Jour. Royal Soc. Interface*, vol. 11: 20140079.<http://dx.doi.org/10.1098/rsif.2014.0079>.
- Stiehl, T., Baran, N., Ho, A. D., Marchianiak-Czohcra, A., 2015, Cell Division Patterns in Acute Myeloid Leukemia Stem-like Cells Determine Clinical Course: A Model to Predict Patient Survival. *Cancer Res.*, vol. 75, no. 6: 940 – 949. doi: 10.1158/0009-5472.CAN-14-2508.
- Strogatz, S. H., 2001, *Nonlinear Dynamics and Chaos: With Applications to Physics, Biology, Chemistry, and Engineering*. Perseus Books Pub, LLC, Canada.
- Supriyadi, E., Wijayanto, P. H., Veerman, A. J. P., dkk, 2011, Immunophenotypic Pattern of Childhood Acute Leukemias in Indonesia. *Asian Pacific Journal of Cancer Prevention*, vol. 12: 3381 – 3387.
- Supriyadi, E., Purwanto, I., Widajanto, P. H., 2013, Terapi Leukimia Mieloblastik Akut Anak: Protokol Ara-C, Doxoubycine dan Etoposide (ADE) vs Modifikasi Nordic Society of Pediatric Hematology and Oncology)m-NPHO), *Sari Pediatri*, vol. 14, no. 6: 345 – 350.

- Takahashi, S., 2011, Downstream Molecular Pathways of FLT3 in the pathogenesis of Acute Myeloid Leukemia: Biology and Therapeutic Implications, *Journal of Hematology and Oncology*, vol. 4, no. 13.
- Tan, W. H., Popel, A. S., Mac-Gabhann, F., 2013, Computational Model of Gab $\frac{1}{2}$ Dependent VEGFR2 Pathway to AKt Activation, *PLoS ONE*, vol. 8, no. 6:e67438. DOI:10.1371/journal.pone.0067438.
- Tayyab, M., Khan, M., Iqbal, Z., dkk, 2014, Distinct Gene Mutations, their Prognostic Relevance and Molecularly Targeted Therapies in Acute Myeloid Leukemia (AML), *J Cancer Sci. Ther.*, vol. 6, no. 9:337 – 349.
- Thol, F., Schlenk, F. S., Heuser, M., Ganser, A., 2015, How I treat refractory and early relapsed acute myeloid leukemia. *Blood*, vol. 126, no. 3:319–327.
- Tian, T. & Song, J., 2012, Mathematical Modelling of THE MAPK Kinase Pathway Using Proteomic Datasets. *Plos One*, vol. 7, no. 8:e42230.
- Tian, T. & Wu, F., 2013, Robustness Analysis of THE PI3K/AKT Cell Signaling Module, *Journal of Medical and Bioengineering*, vol. 2, no. 2: 93–97.
- Verhulst, F., 1996, *Nonlinear Differential Equations and Dynamical Systems*. Springer-Verlag, Germany.
- Wang, G., 2014. *Analysis of Complex Diseases*, CRC Press, Taylor & Francis Group
- Wang, G. & Li, T., 2014, Computer Aided Targeting of The PI3K/AKT/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities. *Int. J. Molecular Sciences*, vol. 15: 18856-18891; DOI:10.3390/ijms151018856.
- Warr, M. R., Pietras, E. M, Passegue, E., 2011, Mechanism Controlling Hematopoietic Stem Cell Functions During Normal Hematopoiesis and Hematological Malignancies, *Advanced Reviews, WIREs System Biology and Medicine*, John Wiley & Sons, Inc.

- Wee, K. B. & Aguda, B. D., 2006, Akt Versus p53 in a Network of Oncogenes and Tumor Suppressor Genes Regulating Cell Survival and Death. *Biophysics*, vol. 91: 857 – 865.
- Whichard, Z. L., Sarkar, C. A., Kimmel, M., Corey, S. J., 2010, Hematopoiesis and Its Disorder: A Systems Biology Approach. *Blood*, vol. 115, no. 12: 2339 - 2347. doi:10.1182/blood-2009-08-215798.
- Wiggins, S., 2003, *Introduction to Applied Nonlinear Dynamical Systems and Chaos*, Springer-Verlag, New York, Inc.
- Windiastuti, E., Nancy, Y. M., Mulatsih, S., Sudarmanto, B., Ugrasena, I. D. G., 2018, *Buku Ajar Hematologi-Onkologi Anak*, IDAI, Salemba-Jakarta.
- Yan-Bin, Y., *Root of Polynomial*, Com S 477/577 Notes, 2017.
- Young, B., O'Dowd, G., Woodford, P., 2014, *Wheater's Functional Histology A text and Colour Atlas*, sixth ed. Churchill Livingstone, Elsevier, Chapt 3.
- Zhang, W., Ly, C., Ishizawa, J., dkk, 2018, Combination Targeting XPO1 and FLT3 Exerts Synergistic Anti Leukemia Effects Throught Induction of Differentiation and Apoptosis in FLT3 Mutated Acute Myeloid Leumekias: From Concept to Clinical Trial, *Haematologica*. 2018, 103 (10): 1642 – 1653.